Marchés français ouverture 4 h 17 min
  • Dow Jones

    33 821,30
    -256,33 (-0,75 %)
     
  • Nasdaq

    13 786,27
    -128,50 (-0,92 %)
     
  • Nikkei 225

    28 436,72
    -663,66 (-2,28 %)
     
  • EUR/USD

    1,2035
    -0,0006 (-0,05 %)
     
  • HANG SENG

    28 551,85
    -583,88 (-2,00 %)
     
  • BTC-EUR

    46 677,18
    +817,75 (+1,78 %)
     
  • CMC Crypto 200

    1 286,02
    +51,61 (+4,18 %)
     
  • S&P 500

    4 134,94
    -28,32 (-0,68 %)
     

Global Tissue Engineered Skin Substitutes Market to Reach $909 Million by 2027

ReportLinker
·19 min de lecture

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 6. - Influencer Pool: 913. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tissue Engineered Skin Substitutes Industry" - https://www.reportlinker.com/p06033134/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.



Abstract:
- Global Tissue Engineered Skin Substitutes Market to Reach $909 Million by 2027
- Amid the COVID-19 crisis, the global market for Tissue Engineered Skin Substitutes estimated at US$670.3 Million in the year 2020, is projected to reach a revised size of US$909 Million by 2027, growing at a CAGR of 4.4% over the analysis period 2020-2027. Biological, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$406.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Synthetic segment is readjusted to a revised 4.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $197.4 Million, While China is Forecast to Grow at 4.2% CAGR
- The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$197.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.
- Biosynthetic Segment to Record 4.1% CAGR
- In the global Biosynthetic segment, USA, Canada, Japan, China and Europe will drive the 4.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$102.2 Million in the year 2020 will reach a projected size of US$136.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$101.6 Million by the year 2027.

Select Competitors (Total 33 Featured) -

  • Amarantus Bioscience Holdings, Inc.

  • BSN medical

  • ConvaTec Group PLC

  • Integra LifeSciences Corporation

  • Kerecis

  • LifeNet Health

  • Mallinckrodt

  • Medline Industries, Inc.

  • MiMedx

  • Mölnlycke Health Care AB

  • Organogenesis Inc.

  • Regenicin

  • Smith & Nephew

  • Tissue Regenix




Read the full report: https://www.reportlinker.com/p06033134/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Tissue Engineered Skin Substitutes Competitor Market Share
Scenario Worldwide (in %): 2020E
Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Tissue Engineered
Skin Substitutes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for Tissue Engineered Skin
Substitutes by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Biological by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 4: World 7-Year Perspective for Biological by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 5: World Current & Future Analysis for Synthetic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 6: World 7-Year Perspective for Synthetic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 7: World Current & Future Analysis for Biosynthetic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World 7-Year Perspective for Biosynthetic by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Acute by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 10: World 7-Year Perspective for Acute by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 11: World Current & Future Analysis for Chronic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Chronic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 13: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World 7-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 15: World Current & Future Analysis for Wound Care
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 16: World 7-Year Perspective for Wound Care Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 17: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 18: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
Market Analytics
Table 19: USA Current & Future Analysis for Tissue Engineered
Skin Substitutes by Product - Biological, Synthetic and
Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 20: USA 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 21: USA Current & Future Analysis for Tissue Engineered
Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 22: USA 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 23: USA Current & Future Analysis for Tissue Engineered
Skin Substitutes by End-Use - Hospitals, Wound Care Centers and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 24: USA 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

CANADA
Table 25: Canada Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 26: Canada 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 27: Canada Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 28: Canada 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 29: Canada Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 30: Canada 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

JAPAN
Table 31: Japan Current & Future Analysis for Tissue Engineered
Skin Substitutes by Product - Biological, Synthetic and
Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 32: Japan 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 33: Japan Current & Future Analysis for Tissue Engineered
Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 34: Japan 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 35: Japan Current & Future Analysis for Tissue Engineered
Skin Substitutes by End-Use - Hospitals, Wound Care Centers and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Japan 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

CHINA
Table 37: China Current & Future Analysis for Tissue Engineered
Skin Substitutes by Product - Biological, Synthetic and
Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 38: China 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 39: China Current & Future Analysis for Tissue Engineered
Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 40: China 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 41: China Current & Future Analysis for Tissue Engineered
Skin Substitutes by End-Use - Hospitals, Wound Care Centers and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 42: China 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

EUROPE
Market Facts & Figures
Market Analytics
Table 43: Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 44: Europe 7-Year Perspective for Tissue Engineered Skin
Substitutes by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2020 & 2027

Table 45: Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 46: Europe 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 47: Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 48: Europe 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 49: Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 50: Europe 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

FRANCE
Table 51: France Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 52: France 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 53: France Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 54: France 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 55: France Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 56: France 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

GERMANY
Table 57: Germany Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 58: Germany 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 59: Germany Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 60: Germany 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 61: Germany Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 62: Germany 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

ITALY
Table 63: Italy Current & Future Analysis for Tissue Engineered
Skin Substitutes by Product - Biological, Synthetic and
Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 64: Italy 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 65: Italy Current & Future Analysis for Tissue Engineered
Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 66: Italy 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 67: Italy Current & Future Analysis for Tissue Engineered
Skin Substitutes by End-Use - Hospitals, Wound Care Centers and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Italy 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

UNITED KINGDOM
Table 69: UK Current & Future Analysis for Tissue Engineered
Skin Substitutes by Product - Biological, Synthetic and
Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 70: UK 7-Year Perspective for Tissue Engineered Skin
Substitutes by Product - Percentage Breakdown of Value Sales
for Biological, Synthetic and Biosynthetic for the Years 2020 &
2027

Table 71: UK Current & Future Analysis for Tissue Engineered
Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 72: UK 7-Year Perspective for Tissue Engineered Skin
Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 73: UK Current & Future Analysis for Tissue Engineered
Skin Substitutes by End-Use - Hospitals, Wound Care Centers and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 74: UK 7-Year Perspective for Tissue Engineered Skin
Substitutes by End-Use - Percentage Breakdown of Value Sales
for Hospitals, Wound Care Centers and Other End-Uses for the
Years 2020 & 2027

REST OF EUROPE
Table 75: Rest of Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 76: Rest of Europe 7-Year Perspective for Tissue
Engineered Skin Substitutes by Product - Percentage Breakdown
of Value Sales for Biological, Synthetic and Biosynthetic for
the Years 2020 & 2027

Table 77: Rest of Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 78: Rest of Europe 7-Year Perspective for Tissue
Engineered Skin Substitutes by Application - Percentage
Breakdown of Value Sales for Acute and Chronic for the Years
2020 & 2027

Table 79: Rest of Europe Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 80: Rest of Europe 7-Year Perspective for Tissue
Engineered Skin Substitutes by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Wound Care Centers and Other
End-Uses for the Years 2020 & 2027

ASIA-PACIFIC
Table 81: Asia-Pacific Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 82: Asia-Pacific 7-Year Perspective for Tissue Engineered
Skin Substitutes by Product - Percentage Breakdown of Value
Sales for Biological, Synthetic and Biosynthetic for the Years
2020 & 2027

Table 83: Asia-Pacific Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 84: Asia-Pacific 7-Year Perspective for Tissue Engineered
Skin Substitutes by Application - Percentage Breakdown of Value
Sales for Acute and Chronic for the Years 2020 & 2027

Table 85: Asia-Pacific Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 86: Asia-Pacific 7-Year Perspective for Tissue Engineered
Skin Substitutes by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Wound Care Centers and Other End-Uses for
the Years 2020 & 2027

REST OF WORLD
Table 87: Rest of World Current & Future Analysis for Tissue
Engineered Skin Substitutes by Product - Biological, Synthetic
and Biosynthetic - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 88: Rest of World 7-Year Perspective for Tissue
Engineered Skin Substitutes by Product - Percentage Breakdown
of Value Sales for Biological, Synthetic and Biosynthetic for
the Years 2020 & 2027

Table 89: Rest of World Current & Future Analysis for Tissue
Engineered Skin Substitutes by Application - Acute and Chronic -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 90: Rest of World 7-Year Perspective for Tissue
Engineered Skin Substitutes by Application - Percentage
Breakdown of Value Sales for Acute and Chronic for the Years
2020 & 2027

Table 91: Rest of World Current & Future Analysis for Tissue
Engineered Skin Substitutes by End-Use - Hospitals, Wound Care
Centers and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 92: Rest of World 7-Year Perspective for Tissue
Engineered Skin Substitutes by End-Use - Percentage Breakdown
of Value Sales for Hospitals, Wound Care Centers and Other
End-Uses for the Years 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 33
Read the full report: https://www.reportlinker.com/p06033134/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001